Good news | Scientific research and innovation continue to make strides! Haibu Pharmaceutical has obtained another patent authorization.

On April 12, the patent "Hydrogel and its Production Method" applied for by Haibu Pharmaceutical was granted patent authorization by the National Intellectual Property Administration! The acquisition of this patent once again demonstrates Haibu Pharmaceutical's research foundation and technological innovation strength.

Total number of patent applications: 61

Authorized patents: 16

Patents have become a core element in market competition as an important intellectual property.In the future, Haibu Pharmaceutical will continue to increase investment in research and development and talent cultivation, strengthen research innovation advantages, enhance technological innovation capabilities, promote the transformation of scientific achievements into practical applications, provide strong technical support for company projects, continuously improve customer service quality and efficiency to meet diversified market demands.

Beijing Haibu Pharmaceutical Technology Co., Ltd. (referred to as "Haibu Pharmaceutical") was established in 2005 and is a high-tech enterprise with "chemical drug R&D" as its core capability. It has a research center in Beijing, an active pharmaceutical ingredient (API) and formulation pilot verification center, and a GMP industrial production base. It mainly engages in CRO services for APIs and formulations, MAH joint licensing, API-related applications, and commercial supply of pharmaceutical intermediates.It has rich experience in R&D transfer production registration applications for various dosage forms such as chemical raw materials drugs, oral solids, liquid preparations, sterile injections, external preparations etc. The R&D products cover multiple therapeutic areas including anti-tumor, anti-depression, anti-epilepsy, anti-anxiety cardiovascular diseases digestive system respiratory system etc.

Haibu Pharmaceutical has been awarded the title of "Top 20 Chinese Pharmaceutical R&D Companies" for many consecutive years and recognized as a "Specialized & Innovative Enterprise" in Beijing,"National High-tech Enterprise", "Beijing Science & Technology Research Development Institution", "Beijing Yizhuang Enterprise Innovation Center", etc.